Review Article

Singular Features of Trypanosomatids’ Phosphotransferases Involved in Cell Energy Management

Claudio A. Pereira, León A. Bouvier, María de los Milagros Cámara, and Mariana R. Miranda

Laboratorio de Biología Molecular de Trypanosoma cruzi (LBMTC), Instituto de Investigaciones Médicas “Alfredo Lanari”, Universidad de Buenos Aires and CONICET, Combatientes de Malvinas 3150, 1427 Buenos Aires, Argentina

Correspondence should be addressed to Claudio A. Pereira, cpereira@retina.ar

Received 21 December 2010; Revised 23 January 2011; Accepted 8 February 2011

Academic Editor: Ariel M. Silber

Copyright © 2011 Claudio A. Pereira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Trypanosomatids are responsible for economically important veterinary affections and severe human diseases. In Africa, Trypanosoma brucei causes sleeping sickness or African trypanosomiasis, while in America, Trypanosoma cruzi is the etiological agent of Chagas disease. These parasites have complex life cycles which involve a wide variety of environments with very different compositions, physicochemical properties, and availability of metabolites. As the environment changes there is a need to maintain the nucleoside homeostasis, requiring a quick and regulated response. Most of the enzymes required for energy management are phosphotransferases. These enzymes present a nitrogenous group or a phosphate as acceptors, and the most clear examples are arginine kinase, nucleoside diphosphate kinase, and adenylate kinase. Trypanosoma and Leishmania have the largest number of phosphotransferase isoforms ever found in a single cell; some of them are absent in mammals, suggesting that these enzymes are required in many cellular compartments associated to different biological processes. The presence of such number of phosphotransferases support the hypothesis of the existence of an intracellular enzymatic phosphotransfer network that communicates the spatially separated intracellular ATP consumption and production processes. All these unique features make phosphotransferases a promising start point for rational drug design for the treatment of human trypanosomiasis.

1. Introduction

Protozoan pathogens constitute an important group of parasites with medical and veterinary importance. Among them, Leishmania spp. and Trypanosoma spp. are examples of mammalian parasites. About half a million people are infected by parasites of the T. brucei group in Africa, 11–18 million with T. cruzi in the Americas, and 12 million with Leishmania in Africa, Asia, Europe, and Americas [1, 2]. The life cycles of Leishmania and T. cruzi involve an obligatory intracellular stage in mammals, in contrast to the exclusively extracellular parasites of the T. brucei group. Both Leishmania and T. cruzi invade host cells, while Leishmania lives inside parasitophorous vacuoles and T. cruzi escapes from the vacuole and lives in the cytoplasm of the host cell. In both cases, the parasites have to adhere to the host cell surface in order to invade the cell and survive under harsh conditions of the host cytoplasm. Trypanosoma and Leishmania also present an insect stage during its life cycle, all T. brucei group organisms are transmitted by tsetse flies of the genus Glossina, T. cruzi is transmitted by haematophagous insects belonging to the family Reduviidae, and Leishmania spp. are transmitted from man to man by different species of sandflies. Therefore, a common feature amongst parasitic protozoan organisms is their ability to adapt their metabolism to a wide range of environmental conditions and selection pressures, which include the availability and quality of carbon sources in the different mammalian and insect hosts [3]. Therefore, enzymes associated in energy metabolism are important candidates to rational designing of trypanocidal therapeutic drugs.
2. A General View of Trypanosomatids’ Energy Metabolism

Even though trypanosomes share energy metabolism features with higher eukaryotes, they present unique characteristics which differentiate them from their metazoan host. Furthermore, the exact nature of their energy metabolism varies sensibly not only between trypanosomatid species [3] but also between different life cycle stages of any given species [4]. It has been considered that these differences evolved from the variable nutrient supply in the particular environments of each trypanosomatid [5]. However, the metabolic disparities among different trypanosomatid species, which share the same host, indicate that metabolite availability alone cannot be the reason for the energy metabolism strategy exploited in each case [6].

To date, the most extensive experimental studies of trypanosome energy metabolism have been conducted in T. brucei, more precisely on the mammalian host associated to the bloodstream form and procyclic trypomastigote present in the tsetse fly midgut. Both of these life cycle stages are easily cultured in defined media in vitro.

The completion of the respective genome projects has enabled to in silico deduce a general metabolic pathway map for these trypanosomes; however this strategy alone misses to determine the presence and importance of single metabolic steps in each life cycle stage [5].

Although trypanosomes possess all enzymatic components needed for the glycolytic pathway, the first seven enzymes are contained inside specialized microbodies from the peroxisome class called glycosomes [7]. These are rounded single membrane-bound organelles with a diameter of approximately 300 nm [8]. Many proteins that are localized to the interior of glycosomes contain specific targeting signals called PTS1 and PTS2 [9]. Furthermore the specialized matrix protein import system shares mechanistic similarities with the endoplasmic reticulum/proteasome degradation process which suggests that glycosomes, as well as peroxisomes and glyoxysomes, all share a common evolutionary origin [10, 11]. The key role of glycosomes in trypanosome energy metabolism becomes evident with the fact that the bloodstream form of T. brucei depends exclusively on glycolysis for ATP generation. The end metabolite of this pathway of hexose sugars corresponds to excreted pyruvate [12]. Intriglycosomal redox balance is maintained using a glycerol-3-phosphate dehydrogenase shuttle. The reoxidation of the glycolysis-derived NADH coenzyme is accomplished inside this organelle through an NAD-linked glycerol-3-phosphate dehydrogenase which reduces dihydroxyacetone phosphate to glycerol-3-phosphate [7]. In the presence of molecular oxygen, after exportation from the glycosome this molecule is directed to the mitochondria where it becomes reoxidized to dihydroxyacetone phosphate by the cyanide-insensitive trypanosome alternative oxidase [13] which then returns to the glycosome. On the other half of the glycolytic pathway the final product that leaves the glycosome is 3-phosphoglycerate. In the cytosol the remaining three glycolytic steps take place producing pyruvate as end-product, thus the net ATP yield corresponds to two molecules per glucose. However in anaerobic conditions the yield is halved due to the inability to reoxidize glycerol-3-phosphate, and glycerol becomes an end-product equimolar to pyruvate [5]. The essential role of glycolysis in trypanosome energy metabolism and its particular and divergent strategy of glycosomal confinement, which distinguishes them from other eukaryotes, constitutes a clear and plausible target for chemotherapeutic molecules [14]. RNAi-induced down regulation of components of the glycosomal matrix protein import system produces a relocalization of glycolytic enzymes to the cytosol which is accompanied by a lethal phenotype [15, 16]. One of the possible explanations for the essential compartmentalization of glycolytic enzymes relies on the lack of feedback regulation determined for the trypanosome enzymes hexokinase and phosphofructokinase [17–19]. Both of these initial steps of the glycolytic pathway consume ATP that is recovered in later steps as well as the net ATP gain derived from the pathway. In the absence of specific regulation ATP produced by glycolysis would boost the flux through these enzymes above the capacity of the enzymes downstream with lethal accumulation of intermediate metabolites and cellular depletion of ATP. In this sense confinement within a membranous organelle from the final ATP synthesis steps constitutes an alternative regulatory strategy to unregulated enzymes [16].

Returning to the metabolism of bloodstream form T. brucei, the end-product of glucose metabolism is pyruvate. It cannot be further metabolized because during this stage pyruvate dehydrogenase, the tricarboxylic acid (TCA) cycle, and the respiratory chain are absent from the mitochondrial compartment. All the members of the order Kinetoplastida are characterized by a single large mitochondrion which contains a unique structure named kinetoplast [12]. This structure is constituted by a gigantic network of concatenated circular DNAs which represent the mitochondrial genome. Among these molecules, those termed maxicircles encode mitochondrial rRNAs and respiratory chain subunits [20]. Evidence for the expendable nature of mitochondrial metabolic pathways during bloodstream stage derive from the findings that T. equiperdum and T. evansi actually correspond to T. brucei mutants which, respectively, contain relics or completely lack kinetoplast DNA [21]. Although ATP synthase is present, it hydrolyzes ATP in order to maintain proton gradient across the inner mitochondrial membrane essential for the translocation of nuclear-encoded proteins into the mitochondrial matrix [22, 23].

On the other hand, T. brucei procyclic trypomastigotes contain a complete set of mitochondrial respiratory chain complexes and all the enzymes responsible for the tricarboxylic acid cycle. Despite the suggestive potential aerobic metabolism, glucose catabolism end-products indicate a predominant fermentation activity. Additionally inhibition of respiration and F0/F1-ATP synthase has no effect on intracellular ATP concentration [24]. Apart from carbon dioxide, succinate and acetate are the main excreted metabolites [25]. A fraction of the succinate derives from intraglycosomal redox balance maintenance. Glycosomal NADH is reoxidized by a glycosomal malate dehydrogenase which reduces oxaloacetate to malate, and after the subsequent production
of fumarate, another glycosomal reducing reaction yields succinate which is then secreted [26]. The remaining succinate is produced inside the mitochondria through a set of the enzymes relative to the tricarboxylic acid cycle, during the degradation of proline and glutamate [12]. Furthermore mitochondrial pyruvate is not oxidized to carbon dioxide and water [27, 28]. This molecule is decarboxylated, and the resulting acetyl-CoA is converted to acetate yielding an additional molecule of ATP [29, 30]. Acetate represents the essential precursor for lipid biosynthesis in procyclic form of T. brucei [31]. The diverse functions of components of the tricarboxylic acid cycle allow concluding that in these organisms there is no cycle [12].

Trypanosomes in culture universally prefer glucose as carbon source for energy metabolism; however in the digestive environments endured during the insect stages, it is accepted that carbohydrates are only available in limited quantities. Therefore it has been demonstrated that amino acids, such as proline and threonine, can be metabolized for ATP production. This has also been studied in T. cruzi epimastigotes which although prefer to use glucose over amino acids as an energy substrate [32]. Under aerobic conditions they produce, in addition to CO₂, considerable amounts of succinate, L-alanine, and acetate [33]. Epimastigotes produce ammonia only after the glucose in the medium has been exhausted [32]. An axenic culture model suggests that T. cruzi amastigotes mostly use glycolytic metabolism for ATP production [34]. Amastigotes also ferment glucose to succinate and acetate, but do not seem to secrete ammonia and have little need for the oxidation of amino acids. All these metabolic pathways are summarized in Figure 1.

Maintenance of energy homeostasis requires coordinate regulatory responses according to the surrounding media composition inside the hosts. Most of the enzymes required for energy management, participating in these adaptation processes, are phosphotransferases with a nitrogenous group or a phosphate as acceptors (ECs 2.7.3 and 2.7.4, resp.), such as arginine kinase (AK), nucleoside diphosphate kinase (NDPK), and adenylate kinase (ADK).

### 3. Phosphotransferases in Trypanosomatids

Phosphotransferase families related to cell energy management are highly represented in trypanosomatid organisms; for example, since most of the organisms express one to three adenylate kinase isoforms in each cell, T. brucei has seven isoforms targeted to different subcellular structures, such as flagellum, glycosome, mitochondrion, and cytoplasm [35, 36]. L. major and T. cruzi also have six putative adenylate kinase isoforms according to our data and the currently available genome projects [37, 38]. The presence of such number of phosphotransferases and the predicted subcellular localization of each isoform support the hypothesis of the existence of an enzymatic phosphotransfer network that communicates the spatially separated intracellular ATP consumption and production processes [35, 39, 40]. In other organisms, energetic homeostasis is maintained by remodeling this phosphotransfer network. For example, in mammals the lack of muscle creatine kinase is complemented by glycolytic enzymes and adenylate kinase; in a similar way, the suppression of the adenylate kinase gene produces an upregulation of glycolytic enzymes and creatine kinase [41–43].

Since phosphotransferases participate in a variety of metabolic routes leading to many crucial compounds essential for trypanosomatid organisms, these families of enzymes become interesting targets for drug design.

#### 3.1. Arginine Kinases

Phosphoarginine and phosphocreatine, generally called phosphagens, play a critical role as energy reserve because the high-energy phosphate can be transferred to adenosine diphosphate (ADP) when the renewal of adenosine triphosphate (ATP) is needed. It has been proposed that phosphoarginine supports bursts of cellular activity until metabolic events such as glycogenolysis, glycolysis, and oxidative phosphorylation are switched on [44]. Phosphoarginine synthesis also allows the cells to operate with low ATP levels since it may constitute a usable pool of the high-energy phosphate. Phosphagens act as reservoir, not only of ATP, but also of inorganic phosphate that is mostly returned to the medium by the metabolic consumption of ATP [45]. Arginine kinase (ATP: arginine phosphotransferase; EC: 2.7.3.3) catalyzes the reversible transphosphorylation between N-phospho-L-arginine and ADP [44]:

\[
\text{Mg} \cdot \text{ATP} + \text{L-arginine} \rightarrow \text{P-L-arginine} + \text{Mg} \cdot \text{ADP} + \text{H}^+ 
\]

(1)

From an evolutionary viewpoint, arginine kinase was included in a family of conserved proteins with phosphotransferase activity, with creatine kinase as the best known member. Arginine kinase is the most widely distributed phosphaen kinase, which is found in Annelida, Coelenterata, Platychelminthes, Nemertea, Mollusca, Phoroniida, Arthropoda, Echinodermata, Hemichordata, and Chordata [46, 47]. In addition, arginine kinases are considered the most closely related member to the ancestral guanidino kinases [48].

In the last decade, the molecular and biochemical characterization of arginine kinases in T. cruzi and T. brucei have been reported [49–53]. Since arginine kinase, an important enzyme involved in the energy supply for the parasite, is absent from mammalian tissues, it becomes a possible target for the future development of chemotherapeutic agents against Chagas’ disease and other parasitic diseases caused by related organisms. For this purpose, a rational approach would involve the validation of the enzyme as a therapeutic target and the search for specific enzyme inhibitors. It was also postulated that arginine kinase could be a useful chemotherapeutic target in pesticides development for the control of cockroach proliferation [54].

Multiple evidence indicates that T. cruzi arginine kinase is strongly regulated by intra- and extracellular conditions: (1) the arginine kinase protein and the associated-specific activity increase continuously along the epimastigote growth curve, suggesting a correlation between the enzyme activity, and the nutrient availability or parasite density [32];
Figure 1: Schematic representation of trypanosomatids' energy metabolism. Enzymes are indicated with numbers: 1, hexokinase; 2, glucose-6-phosphate isomerase; 3, phosphofructokinase; 4, aldolase; 5, triosephosphate isomerase; 6, glyceraldehyde-3-phosphate dehydrogenase; 7, phosphoglycerate kinase; 8, phosphoglycerate mutase; 9, enolase; 10, pyruvate kinase; 11, glyceraldehyde-3-phosphate dehydrogenase; 12, glyceraldehyde-3-phosphate; 13, phosphoenolpyruvate carboxykinase; 14, malate dehydrogenase; 15, fumarase; 16, fumarate reductase; 17, pyruvate phosphate dikinase; 18, pyruvate dehydrogenase complex; 19, acetate:succinate CoA transferase; 20, citrate synthase; 21, α-ketoglutarate dehydrogenase; 22, succinyl-CoA synthetase; 23, succinate dehydrogenase; 24, fumarase; 25, malate dehydrogenase; 26, proline oxidase; 27, Δ′-pyrroline-5-carboxylate reductase; 28, glutamate semialdehyde dehydrogenase; 29, glutamate dehydrogenase; 30, threonine dehydrogenase; 31, acetyl-CoA:glycine C-acetyltransferase; 32, NADP-linked decarboxylating malic enzyme; 33, fructose-1,6-bisphosphatase. Enzymes present in bloodstream forms only are indicated in red, procyclic forms enzymes are in red and black. AOX: alternative oxidase; GPD: FAD-dependent glycerol-3-phosphate dehydrogenase; I: NADH-ubiquinone oxidoreductase (complex I); II: succinate dehydrogenase (complex II); III: cytochrome c oxidase (complex III); IV: cytochrome c oxidase (complex IV); c: cytochrome c1; Q: ubiquinone; F0/F1-ATP synthase; Glc-6-P: glucose-6-phosphate; Fru-6-P: fructose-6-phosphate; Fru-1,6-P2: fructose-1,6-bisphosphate; GAP: glyceraldehyde-3-phosphate; G-1,3-P2: 1,3-bisphosphoglycerate; 3-PGA: 3-phosphoglycerate; 2-PGA: 2-phosphoglycerate; PEP: phosphoenolpyruvate; DHAP: dihydroxyacetone phosphate; glucose-3-phosphate; succ-CoA: succinyl-coenzyme A; acetyl-CoA, acetyl-coenzyme A. For a detailed explanation see the text.

(2) the existence of a relationship between the arginine transport rate, arginine kinase activity and the parasite stage and replication capability was recently described, indicating a critical role of arginine kinase as a regulator of energetic reserves and cell growth [55]; (3) the homologous overexpression of T. cruzi arginine kinase improves the ability of the transfectant cells to grow and resist nutritional and pH stress conditions [51]. Arginine kinase would play a role as a stress resistance factor when expressed in organisms that lack this enzyme, such as yeast and bacteria. Recombinant yeast, expressing crab muscle arginine kinase, showed improved resistance under stress challenges that drain cellular energy,
which were transient pH reduction and starvation [56, 57]. *T. cruzi* epimastigotes treated with hydrogen peroxide presented a time-dependent increase in arginine kinase expression, up to 10-fold, when compared with untreated parasites. Among other oxidative stress-generating compounds tested, only nifurtimox produced more than 2-fold increase in arginine kinase expression [52]. Moreover, parasites over-expressing arginine kinase showed significantly increased survival capability during hydrogen peroxide exposure. These findings suggest the participation of arginine kinase in oxidative stress response systems. It is important to remark that the insect stage of the *T. cruzi* life cycle is frequently exposed to nutritional and pH stress conditions, depending on the feeding status of the vector. For example, the pH of excreted material of the *T. cruzi* vector *T. infestans* varies between 5.7 and 8.9, accordingly with the time after feeding [58]. All these data suggest that arginine kinase is involved in the adaptation of the parasite to environmental changes and stress conditions. Recently, the crystal structure of ligand-free TcAK was determined by molecular replacement methods and refined at 1.9 Å resolution [59]. This information could be a new relevant tool for rational trypanocidal drug design.

Until today no outstanding arginine kinase inhibitors have been found. Only a few compounds have been reported which present a partial inhibition of arginine kinase. For example, the trypanocidal action of green tea (*Camellia sinensis*) catechins against two different developmental stages of *T. cruzi* was demonstrated by Paveto et al. [60]. Furthermore, recombinant *T. cruzi* arginine kinase was 50% inhibited by nanomolar concentrations of these polyphenols (catechin gallate or gallocatechin gallate). In silico docking studies indicated that the flavonoid rutin is an arginine kinase noncompetitive inhibitor and interacts mainly by a hydrophobic force forming an intermolecular complex with the enzyme [61]. Arginine kinase was also inhibited by the arginine analogs, agmatine, canavanine, nitroarginine, and homoarginine [62]. In addition, canavanine and homoarginine also produce a significant inhibition of the epimastigote growth in culture.

### 3.2. Nucleoside Diphosphate Kinases

Nucleoside diphosphate kinases (EC: 2.7.4.6) are enzymes involved in the intracellular nucleotide maintenance that catalyze the reversible transference of high energy phosphates from a nucleoside triphosphate donor to a nucleoside diphosphate acceptor as follows [63]:

\[
\text{N1TP} + \text{N2DP} \rightarrow \text{N1DP} + \text{N2TP}
\] (2)

Although the high energy phosphate is mainly supplied by ATP, these enzymes have broad spectrum substrate specificity and are able to use other ribo- and deoxyribonucleotides having preference for GTP formation [64].

NDPKs are ubiquitous and widely studied enzymes, and they can be divided in two groups according to the primary structure [65]. Group I is composed of canonical NDPKs, which are broadly studied and found in prokaryotes and eukaryotes. They form homotetramers in prokaryotes and homohexamers in eukaryotes [66]. The monomers have molecular mass between 15 and 18 KDa and are highly conserved during evolution; for example, there is about 40% identity between NDPKs from *Escherichia coli* and humans [64]. In contrast, group II is formed by divergent NDPKs that are present only in eukaryotes. Proteins included in this group are still poorly characterized and contain one or more NDPK's canonical domains and N-terminal or C-terminal extensions. Some domains such as DM10 domains are present in single copy in this type of NDPKs at the N-terminus. These domains are also contained in other unrelated proteins which have three repeats of this domain. There are only a few studies made on these proteins, in one of them they could associate DM10 domains to protein-axoneme connection [67]. However, the function of NDPK's DM10 domain remains unexplored. Thioredoxin domains are also found in this group of NDPKs, and it was postulated its participation in regulation of NDPK activity by a redox mechanism [68].

NDPKs are also involved in numerous and diverse biological processes. Because of the phosphohistidine enzyme formation in the transference reaction, the phosphate can also be transferred to different acceptors such as other proteins in serine or threonine residues and was postulated to participate in protein G activation by GTP supplement, so NDPKs are implicated in transduction pathways [69–74] playing many functions in, for example, development, proliferation, differentiation, and apoptosis [65, 72, 75–79]. Interestingly, it was also observed that some NDPKs have several roles in DNA processing. Human beings have ten NDPK isoforms (NM23-H1 to 10), five of which were found to interact to nucleic acids. NM23-H2 is considered to be a transcription factor because of its capacity to bind to specific DNA sequences, and NM23-H1, H5, H7, and H8 had 3'-5' exonuclease activity in vitro. All these characteristics together with others, as recognition, cleavage, and structural modification of DNA molecules, allow the association between NDPKs and DNA repair mechanisms [77, 80–82].

In the context of studying the biological function of an enzyme, the subcellular localization may be a critical point to establish. Being multifunctional enzymes, NDPKs have been found in numerous subcellular compartments such as cytoplasm, nucleus, mitochondria, intermembrane space, plasmatic membrane, and flagellum from different organisms [82–88]. Considering that NDPKs are involved in phosphotransfer networks their subcellular distribution might be related to an efficient energy distribution inside the cells [39].

Trypanosomatid's NDPKs are of particular interest due to its inability to synthesize purines de novo relying on NDPKs for nucleotide recycling [89]. For this reason these enzymes are considered potential therapeutic targets for trypanosomiasis such as Chagas disease. *T. cruzi* has four putative isoforms of NDPK, TcNDPK1–4. TcNDPK1 is the unique canonical isoform, while TcNDPK2, 3, and 4 correspond to group II variants. Isoforms 2 and 3 have one DM10 domain preceding the catalytic region, and variant 4 has unknown N- and C-terminal extensions. The orthologous
genes of these enzymes are also present in the genomes of the related parasites *T. brucei* and *L. major*, except for the absence of TcNDPK4 in the latter [90]. The first report of NDPK activity in trypanosomatids was published in 1995, where Ulloa et al. detected activity in different subcellular fractions including membranes and purified a soluble NDPK from *T. cruzi* epimastigotes with biochemical properties similar to canonical enzymes, probably corresponding to TcNDPK1 [91]. TcNDPK1 has a molecular mass of 16 KDa and like eukaryotic NDPKs forms homohexamers [92]. In addition, it is expressed in trypanomastigote and amastigote stages [90]. This is an interesting enzyme because it showed not only phosphotransferase activity but also DNase activity with similar rates to commercial nucleases [93]. This new activity was extensively characterized in NM23-H2, the human orthologous of TcNDPK1, and a Lys inside the catalytic site seems to be responsible for it [94]. As *T. cruzi* genomic DNA is also susceptible to TcNDPK1 nuclease activity, it evidences that TcNDPK1 could act at nuclear level, for example, being component of programmed cell death machinery in trypanosomatid organisms [86, 95]. Reinforcing this idea, *T. brucei*-related NDPK was localized mainly in the nucleus of the parasites [96]; conversely it was also identified as a secreted protein [97]. Other results were obtained for members of Leishmania genus; in *L. major* this isoform was associated to microsomal fractions, and in *L. amazonensis* it is secreted and involved in macrophage infection [98, 99]. In *T. cruzi* it is still not clear the localization of the unique canonical isoform. It could be possible that the enzyme has several positions inside the cell and can move from one to another in response to stimuli. In this context a regulation by compartmentalization or phosphorylation is expected as was reported for *T. brucei* [100].

TcNDPK2, a longer NDPK isoform from *T. cruzi*, is a protein of 37 KDa whose first 88 amino acids correspond to the DM10 domain. It is expressed in the three major stages of *T. cruzi* life cycle, and apparently it has distinct regulation from TcNDPK1 because it is inhibited at high substrate concentration [90]. Using immunofluorescence and biochemical techniques we recently demonstrated that TcNDPK2 isoform is a microtubules-associated enzyme mainly localized in the cytoskeleton and flagellum (Miranda et al., unpublished results). TcNDPK2-like NDPKs are conserved in a wide range of eukaryotes with motile axoneme, from unicellular to superior organisms. For example, *T. brucei* orthologous genes codify for an NDPK found in parasite’s flagella [101, 102], and in humans the related protein (NM23-H7) is also expressed in flagella-containing cells such as spermatozooids [103]. These are interesting results because they suggest a common possible function for TcNDPK2-like enzymes such as GTP supplying for tubulin polymerization and thus being involved in microtubule dynamics. DM10 domains present in this type of NDPK have not been investigated till the moment. However, we recently demonstrate, by expression of truncated and fusion variants of TcNDPK2 in *T. cruzi*, that the DM10 domain is sufficient and necessary for cytoskeleton delivery of the enzyme (Miranda et al., unpublished results). In addition, it is possible that DM10 domains were implicated in flagella-targeting machinery, a poorly understood process yet. Importantly, trypanosomatids are considered model organisms for the study of human illness based on cilia and flagella disorders, since NM23-H7 is associated to cone rod dystrophy, a progressive retinal disorder, then the study of TcNDPK2-related enzymes opens new insights in this interesting field.

There is an increasing amount of information about NDPKs that evidence their participation in many diverse biological processes. NDPKs seem to be key metabolic enzymes, thus further studies need to be made in trypanosomatids to understand how they work, to understand their role in metabolism and pathogenesis.

### 3.3. Adenylate Kinases

One of the enzymes related to cell energy management is adenylate kinases, which are ATP:AMP phosphotransferases. These enzymes are involved in the homeostasis of adenine nucleotides by interconversion of the adenine nucleotide pool, which includes ATP synthesis from ADP and an increase in the ATP energetic potential. They catalyze reversible phosphotransfer between ADP, ATP, and AMP molecules, which have been implicated in processing metabolic signals associated with cellular energy utilization [104–106]:

\[ \text{Mg}^{2+} \cdot \text{ADP} + \text{ADP} \rightarrow \text{Mg}^{2+} \cdot \text{ATP} + \text{AMP} \] (3)

Recent evidence indicates that adenylate kinases facilitate intracellular energetic communication. In typical mammalian cells the loss of adenylate kinase function can be complemented by activation of creatine kinase phosphotransfer [40, 107]. Furthermore a similar role can be attributed to creatine and adenylate kinases, being both implicated in the renewal of ATP from ADP and a phosphorylated compound. In some organisms they participate in muscle contraction, metabolic sensing of K⁺-ATP channels [106–108], and cell motility. In unicellular organisms such as *Tetrahymena* and *Paramecium*, adenylate kinases are involved in the ATP-regenerating system required for ciliary and flagellar movement.

They can be considered key enzymes in life support as they are present in almost all living organisms; they are distributed from bacteria to vertebrates.

The tridimensional structure of adenylate kinases can be decomposed into three subdomains, based on the functional roles and induced fit movements: the NMP-bind and LID domains, the moving parts, and the CORE domain that is unaffected by substrate binding. The “long” and “short” adenylate kinases classification is based on the differences in the LID domain; LID is an 11-residue segment in the short type, whereas that in the long type consists of 38 residues and the difference leads to drastic changes in the conformation of the LID domain. They are small globular proteins that suffer conformational changes when they interact with their substrate [109]; moreover, in most of the cases they are found as monomers [110].

Adenylate kinases isolated from prokaryotes belong to the long type [111]. Similarly the ADK localized in the chloroplast is also the long type [112]. Considering the chloroplast ADKs and the mitochondrial ADKs to have
Table 1: Characteristics of trypanosomatids’ phosphotransferases. Summary of the main features of arginine kinases (AKs), adenylate kinases (ADKs), and nucleoside diphosphate kinases (NDPKs) isoforms from trypanosomatids. Predicted subcellular localizations are indicated with a question mark. The existence or not of human equivalents (human), N- or C-terminal extensions (N-t and C-t), peroxisomal targeting signal (PTS-1), and DM10 motifs are also detailed.

| Enzyme | Organism                          | Isoform | Localization | Human | Features    |
|--------|-----------------------------------|---------|--------------|-------|-------------|
| AK     | T. cruzi/T. brucei                | 1       | Cytosol      | No    | Canonical   |
|        | T. brucei                         | 2       | ?            | No    | N-t         |
|        |                                   | 3       | ?            | No    | C-t         |
| ADK    | T. cruzi/T. brucei/L. major       | 1       | Flagellum    | Yes   | N-t         |
|        |                                   | 2       | Reservosome (?) | Yes  | —           |
|        |                                   | 3       | Glycosome    | Yes   | PTS-1       |
|        |                                   | 4       | Flagellum    | Yes   | N-t         |
|        |                                   | 5       | Cytosol      | Yes   | Canonical   |
|        |                                   | 6       | Mitochondria | Yes   | —           |
|        | T. brucei                         | 7 (A)   | Flagellum    | Yes   | N-t         |
| NDPK   | T. cruzi/T. brucei/L. major       | 1       | Nucleus (?)  | Yes   | Canonical   |
|        |                                   | 2       | Cytoskeleton | Yes   | DM10        |
|        |                                   | 3       | ?            | Yes   | DM10        |
|        | T. cruzi/T. brucei                | 4       | ?            | Yes   | Putative    |

a prokaryotic origin in view of the endosymbiotic hypothesis, the classification can be subdivided into the eukaryotic short type and the prokaryotic long type. As always there are exceptions to this classification. For example, the cytosolic ADK from S. cerevisiae is the long type [113]. Another interesting case is the long type ADK from Giardia [114]. Giardia belongs to the most primitive group in the Eukaryota, it does not have mitochondria. Consequently it is highly impossible, and Giardia’s ADK has derived from mitochondria. Lastly the third exception is the short type ADK from the bacteria, Micrococcus [115]. Gathering all the information many authors postulate that the long and short types of adenylate kinase have diverged before the appearance of eukaryotes; this hypothesis could perfectly explain why both types of ADKs are found in prokaryotes and eukaryotes [116].

Their function can be related to their subcellular localization. They have been found in the cytoplasm, mitochondrial matrix, chloroplasts [117], and hydrogenosomes [118], structures that can be directly related to energy consumption and generation places. There is absolutely no doubt that adenylate kinases in those structures are responsible for the interconversion of the adenosine nucleotides. On the other hand essential functions have been related to adenylate kinases; for example, null growth is observed in E. coli [119] and S. pombe [120], lacking in their adenylate kinases. On the other hand they can be linked to consumption sites of ATP. For example, in Paramecium it has been proposed that they would be involved in the fast interconversion of ADP to ATP in the process of cilia reactivation [121].

In a few words adenylate kinases can be considered as key enzymes in cell energetic with the ability of doubling the ATP energy potential. They are a key sensor in cell energetic status sensing; thanks to their catalytic activity small variations in the nucleotide pool of ATP and ADP can be reflected as big changes in the AMP pool, increasing in this way the sensibility and response of the AMP responding mechanisms [107]. Lastly they can be linked to cellular energetic communication; under highly demanding energy process in some subcellular structures such as nucleus or flagella, fast relocalization of organelles involved in energy synthesis has been observed [39, 40]. These movements have been considered as mechanisms for reducing the distances between energy consumption and generating places. Even so these mechanisms would not be enough, diffusion processes are slow, so it has been proposed that the energy transport is catalyzed enzymatically. Key enzymes in the phosphotransferase network would be adenylate kinases [122].

In parasitic protozoa adenylate kinases have been detected and characterized. In L. donovani a long LID domain adenylate kinase has been cloned and characterized [123]. The unicellular malaria parasite, P. falciparum (Apicomplexa), presents two adenylate kinase isoforms [124].

In other parasitic protozoa a larger number of isoforms have been characterized. L. major has six putative adenylate kinase isoforms according to the genome project data. In other trypanosomatids, T. brucei and Phytomonas spp, adenylate kinases have been detected in diverse organelles, microbodies, glycosomes [125]. Recently two flagellar, cytoplasmic and mitocondrial associated adenylate kinases were characterized in T. brucei [35, 36]. A large number of isoforms, six in total, have also been described in T. cruzi, with possible flagellar, glycosomal, mitocondrial, and cytoplasmic subcellular localization [37]. The data presented reveals an enormous variability within organisms, which are reflection of their adaptation to their life cycle. In the case of T. cruzi the high number of adenylate kinases can be attributed to the complex life cycle it goes through which involves distinct environments (insect vector gut, mammalian blood, and mammalian host cell cytoplasm) and consequently variable nutritional conditions. Another possible explanation to the highly unusual number of
adenylate kinase can be that they are not only in different subcellular localization but that they are stage specific.

A summary of the main characteristics from each phosphotransferase mentioned in the text is presented in Table 1.

It is evident that hosts and parasites have a large number of differences in terms of their energy metabolism. Trypanosomatids’ enzymes completely absent in mammals, different isoforms in subcellular localization, structure, and number are some of these divergences. Phosphotransferases are mainly involved in crucial processes such as the maintenance of the ATP balance in the cell. Slight disruptions on this equilibrium are usually lethal for all living organisms; in consequence we consider that trypanosomatids’ phosphotransferases are promising targets for rational drug design.

Acknowledgments

This study was supported by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET, PIP 0685) and Agencia Nacional de Promoción Científica y Tecnológica (FONCYT PICT 2005-33431 and PICT 2008-1209). Claudio A. Pereira and Mariana R. Miranda, are members of the career of scientific investigator of CONICET (Argentina); M. M. Cámara and L. A. Bouvier. are research fellows from the same institution.

References

[1] M. P. Barrett, R. J. S. Burchmore, A. Stich et al., “The trypanosomiasis,” Lancet, vol. 362, no. 9394, pp. 1469–1480, 2003.

[2] R. L. Tarleton, R. Reithinger, J. A. Urbina, U. Kitron, and R. E. Gürtler, “The challenges of Chagas disease—grim outlook or glimmer of hope?” PLoS Medicine, vol. 4, no. 12, article e332, 2007.

[3] A. G. M. Tielens and J. J. Van Hellemond, “The electron transport chain in anaerobically functioning eukaryotes,” Biochimica et Biophysica Acta, vol. 1365, no. 1-2, pp. 71–78, 1998.

[4] V. Hannaert, F. Brinaud, F. R. Opperdoes, and P. A. M. Michels, “Evolution of energy metabolism and its compartmentation in Kinetoplastida,” Kinetoplastid Biology and Disease, vol. 2, article no. 11, 2003.

[5] M. L. Ginger, “Niche metabolism in parasitic protozoa,” Philosophical Transactions of the Royal Society B, vol. 361, no. 1465, pp. 101–118, 2006.

[6] A. G. M. Tielens and J. J. Van Hellemond, “Surprising variety in energy metabolism within Trypanosomatidae,” Trends in Parasitology, vol. 25, no. 10, pp. 482–490, 2009.

[7] F. R. Opperdoes and P. Borst, “Localization of non glycolytic enzymes in a microbody like organelle in Trypanosoma brucei: the glycome,” FEBS Letters, vol. 80, no. 2, pp. 360–364, 1977.

[8] F. R. Opperdoes, P. Baudhuin, and J. Coppens, “Purification, morphometric analysis, and characterization of the glycomoses (microbodies) of the protozoan hemoflagellate Trypanosoma brucei,” Journal of Cell Biology, vol. 98, no. 4, pp. 1178–1184, 1984.

[9] F. R. Opperdoes and J. P. Szikora, “In silico prediction of the glycosomal enzymes of Leishmania major and trypanosomes,” Molecular and Biochemical Parasitology, vol. 147, no. 2, pp. 193–206, 2006.

[10] A. Schlüter, S. Fourcade, R. Ripp, J. L. Mandel, O. Poch, and A. Pujol, “The evolutionary origin of peroxisomes: an ER-peroxisome connection,” Molecular Biology and Evolution, vol. 23, no. 4, pp. 838–845, 2006.

[11] T. Gabaldon, B. Snel, F. van Zimmeren, W. Hemrika, H. Tabak, and M. A. Huynen, “Origin and evolution of the peroxisomal proteome,” Biology Direct, vol. 1, article no. 8, 2006.

[12] J. J. Van Hellemond, F. R. Opperdoes, and A. G. M. Tielens, “The extraordinary mitochondrion and unusual citric acid cycle in Trypanosoma brucei,” Biochemical Society Transactions, vol. 33, no. 5, pp. 967–971, 2005.

[13] M. Chaudhuri, R. D. Ott, and G. C. Hill, “Trypanosome alternative oxidase: from molecule to function,” Trends in Parasitology, vol. 22, no. 10, pp. 484–491, 2006.

[14] F. R. Opperdoes and P. A. M. Michels, “Enzymes of carbohydrate metabolism as potential drug targets,” International Journal for Parasitology, vol. 31, no. 5-6, pp. 482–490, 2001.

[15] C. Guerra-Giraldez, L. Quijada, and C. E. Clayton, “Compartmentation of enzymes in a microbody, the glycosome, is essential in Trypanosoma brucei,” Journal of Cell Science, vol. 115, no. 13, pp. 2651–2658, 2002.

[16] J. R. Haanstra, A. van Tuijl, P. Kessler et al., “Compartmentation prevents a lethal turbo-explosion of glycolysis in trypanosomes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 46, pp. 17718–17723, 2008.

[17] M. Nwaogwu and F. R. Opperdoes, “Regulation of glycolysis in Trypanosoma brucei: hexokinase and phosphofructokinase activity,” Acta Tropica, vol. 39, no. 1, pp. 61–72, 1982.

[18] C. N. Cronin and K. F. Tipton, “Kinetic studies on the reaction catalysed by phosphofructokinase from Trypanosoma brucei,” Biochemical Journal, vol. 245, no. 1, pp. 13–18, 1987.

[19] C. N. Cronin and K. F. Tipton, “Purification and regulatory properties of phosphofructokinase from Trypanosoma (Trypanozoon) brucei brucei,” Biochemical Journal, vol. 227, no. 1, pp. 113–124, 1985.

[20] K. Stuart, “Mitochondrial DNA of an African trypanosome,” Journal of cellular biochemistry, vol. 23, no. 1–4, pp. 13–26, 1983.

[21] D. H. Lai, H. Hashimi, Z. R. Lun, F. J. Ayala, and J. Lukes, “Adaptations of Trypanosoma brucei to gradual loss of kinetoplast DNA: Trypanosoma equiperdum and Trypanosoma evansi are petite mutants of T. brucei,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 6, pp. 1999–2004, 2008.

[22] D. P. Nolan and H. P. Voorheis, “The mitochondrion in bloodstream forms of Trypanosoma brucei is energized by the electrogenic pumping of protons catalysed by the FF-ATPase,” European Journal of Biochemistry, vol. 209, no. 1, pp. 207–216, 1992.

[23] A. Schnaufer, G. D. Clark-Walker, A. G. Steinberg, and K. Stuart, “The F-ATP synthase complex in bloodstream stage trypanosomes has an unusual and essential function,” EMBO Journal, vol. 24, no. 23, pp. 4029–4040, 2005.

[24] V. Coustou, S. Besteiro, M. Biran et al., “ATP generation in the Trypanosoma brucei procyclic form: cytosolic substrate level is essential, but not oxidative phosphorylation,” The Journal of biological chemistry, vol. 278, no. 49, pp. 49625–49635, 2003.
S. W. H. Van Weelden, J. J. Van Hellemond, F. R. Opperdoes, and A. G. M. Tielens, "New functions for parts of the Krebs cycle in procyclic Trypanosoma brucei, a cycle not operating as a cycle," Journal of Biological Chemistry, vol. 280, no. 13, pp. 12451–12460, 2005.

S. Besteiro, M. Biran, N. Biteitou et al., "Succinate secreted by Trypanosoma brucei is produced by a novel and unique glycosomal enzyme, NADH-dependent fumarate reductase," Journal of Biological Chemistry, vol. 277, no. 41, pp. 38001–38012, 2002.

S. W. H. Van Weelden, B. Fast, A. Vogt et al., "Procylic Trypanosoma brucei do not use Krebs cycle activity for energy generation," Journal of Biological Chemistry, vol. 278, no. 15, pp. 12854–12863, 2003.

S. W. H. Van Weelden, J. J. Van Hellemond, F. R. Opperdoes, and A. G. M. Tielens, "New functions for parts of the Krebs cycle in procyclic Trypanosoma brucei, a cycle not operating as a cycle," Journal of Biological Chemistry, vol. 280, no. 13, pp. 12451–12460, 2005.

N. Bochud-Allemann and A. Schneider, "Mitochondrial substrate level phosphorylation is essential for growth of procyclic Trypanosoma brucei," Journal of Biological Chemistry, vol. 277, no. 36, pp. 32849–32854, 2002.

L. Rivière, S. W. H. Van Weelden, P. Glass et al., "Acetyl:succinate CoA-transferase in procyclic Trypanosoma brucei. Gene identification and role in carbohydrate metabolism," Journal of Biological Chemistry, vol. 279, no. 44, pp. 45337–45346, 2004.

L. Rivière, P. Moreau, S. Allmann et al., "Acetate produced in the mitochondrion is the essential precursor for lipid biosynthesis in procyclic trypanosomes," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 31, pp. 12694–12699, 2009.

G. D. Alonso, C. A. Pereira, M. S. Remedi et al., "Arginine kinase of the flagellate protozoan Trypanosoma cruzi: regulation of its expression and catalytic activity," FEBS Letters, vol. 498, no. 1, pp. 22–25, 2001.

J. J. Cazzulo, "Aerobic fermentation of glucose by trypanosomatids," FASEB Journal, vol. 6, no. 13, pp. 3153–3161, 1992.

J. C. Engel, B. M. Franke de Cazzulo, A. O. M. Stoppani, J. B. Cannata, and J. J. Cazzulo, "Aerobic glucose fermentation by Trypanosoma cruzi axenic culture amastigote-like forms during growth and differentiation to epimastigotes," Molecular and Biochemical Parasitology, vol. 26, no. 1–2, pp. 1–10, 1987.

M. L. Ginger, E. S. Ngazoa, C. A. Pereira et al., "Intracellular positioning of isofoms explains an unusually large adenyate kinase gene family in the parasite Trypanosoma brucei," Journal of Biological Chemistry, vol. 280, no. 12, pp. 11781–11789, 2005.

T. J. Pullen, M. L. Ginger, S. J. Gaskell, and K. Gull, "Protein targeting of an unusual, evolutionarily conserved adenyate kinase to a eukaryotic flagellum," Molecular Biology of the Cell, vol. 15, no. 7, pp. 3257–3265, 2004.

L. A. Bouvier, M. R. Miranda, G. E. Canepa, J. M. M. Alves, and C. A. Pereira, "An expanded adenyate kinase gene family in the protozoan parasite Trypanosoma cruzi," Biochimica et Biophysica Acta - General Subjects, vol. 1760, no. 6, pp. 913–921, 2006.

N. M. El-Sayed, P. J. Myler, D. C. Bartholomeu et al., "The genome sequence of Trypanosoma cruzi, etiologic agent of chagas disease," Science, vol. 309, no. 5733, pp. 409–415, 2005.

P. P. Dzeja and A. Terzic, "Phosphotransfer networks and cellular energetics," Journal of Experimental Biology, vol. 206, no. 12, pp. 2039–2047, 2003.

P. P. Dzeja, R. Bortolon, C. Perez-Terzic, E. L. Holmuhamedov, and A. Terzic, "Energetic communication between mitochondria and nucleus directed by catalyzed phospho-transfer," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 15, pp. 10156–10161, 2002.

P. P. Dzeja, A. Terzic, and B. Wieringa, "Phosphotransfer dynamics in skeletal muscle from creatine kinase gene-deleted mice," Molecular and Cellular Biochemistry, vol. 256–257, no. 1-2, pp. 13–27, 2004.

E. Janssen, AD. De Groof, M. Wijers et al., "Adenyate kinase 1 deficiency induces molecular and structural adaptations to support muscle energy metabolism," Journal of Biological Chemistry, vol. 278, no. 15, pp. 12937–12945, 2003.

E. Janssen, P. P. Dzeja, E. Oerlemans et al., "Adenyate kinase 1 gene deletion disrupts muscle energetic economy despite metabolic rearrangement," EMBO Journal, vol. 19, no. 23, pp. 6371–6381, 2000.

W. R. Ellington, "Evolution and physiological roles of phosphagen systems," Annual Review of Physiology, vol. 63, pp. 289–325, 2001.

F. J. R. Hird, "The importance of arginine in evolution," Comparative Biochemistry and Physiology, Part B, vol. 85, no. 2, pp. 285–288, 1986.

J. F. Morrison, "Arginine kinase and other invertebrate guanidine kinases," in The Enzymes, P. C. Boyer, Ed., vol. 8, pp. 457–486, Academic Press, New York, NY, USA, 1973.

T. Wallimann, M. Wyss, D. Brdizcka, K. Nicolay, and H. M. Eppenberger, "Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis," Biochemical Journal, vol. 281, no. 1, pp. 21–40, 1992.

T. Suzuki, Y. Kawasaki, T. Furukohri, and W. R. Ellington, "Evolution of phosphagen kinase. VI. Isolation, characterization and cDNA-derived amino acid sequence of lombricine kinase from the earthworm Eisenia fetida, and identification of a possible candidate for the guanidine substrate recognition site," Biochimica et Biophysica Acta, vol. 1343, no. 2, pp. 152–159, 1997.

C. A. Pereira, G. D. Alonso, M. C. Paveto, M. M. Flawià, and H. N. Torres, "L-arginine uptake and L-phosphoarginase synthesis in Trypanosoma cruzi," Journal of Eukaryotic Microbiology, vol. 46, no. 6, pp. 566–570, 1999.

C. A. Pereira, G. D. Alonso, M. C. Paveto et al., "Trypanosoma cruzi arginine kinase characterization and cloning. A novel energetic pathway in protozoan parasites," Journal of Biological Chemistry, vol. 275, no. 2, pp. 1495–1501, 2000.

C. A. Pereira, G. D. Alonso, S. Ivaldi et al., "Arginine kinase overexpression improves Trypanosoma cruzi survival capability," FEBS Letters, vol. 554, no. 1-2, pp. 201–205, 2003.

M. R. Miranda, G. E. Canepa, L. A. Bouvier, and C. A. Pereira, "Trypanosoma cruzi: oxidative stress induces arginine kinase expression," Experimental Parasitology, vol. 114, no. 4, pp. 341–344, 2006.

C. A. Pereira, G. D. Alonso, H. N. Torres, and M. M. Flawià, "Arginine kinase: a common feature for management of energy reserves in African and American flagellated trypanosomatids," Journal of Eukaryotic Microbiology, vol. 49, no. 1, pp. 82–85, 2002.
[54] A. E. Brown and S. H. Grossman, “The mechanism and modes of inhibition of arginine kinase from the cockroach (Periplaneta americana),” Archives of Insect Biochemistry and Physiology, vol. 57, no. 4, pp. 166–177, 2004.

[55] C. A. Pereira, G. D. Alonso, S. Ivaldi et al., “Arginine metabolism in Trypanosoma cruzi is coupled to parasite stage and replication,” FEBS Letters, vol. 526, no. 1–3, pp. 111–114, 2002.

[56] F. Canonaco, U. Schlattner, P. S. Pruett, T. Wallimann, and U. Sauer, “Functional expression of phosphagen kinase systems confers resistance to transient stresses in Saccharomyces cerevisiae by buffering the ATP pool,” Journal of Biological Chemistry, vol. 277, no. 35, pp. 31303–31309, 2002.

[57] F. Canonaco, U. Schlattner, T. Wallimann, and U. Sauer, “Functional expression of arginine kinase improves recovery from pH stress of Escherichia coli,” Biotechnology Letters, vol. 25, no. 13, pp. 1013–1017, 2003.

[58] A. H. Kollien, T. Grospietsch, T. Kleffmann, I. Zerbst-Boroffka, and G. A. Schau, “Ionic composition of the rectal contents and excreta of the reduviid bug Triatoma infestans,” Journal of Insect Physiology, vol. 47, no. 7, pp. 739–747, 2001.

[59] P. Fernandez, A. Haouz, C. A. Pereira, C. Aguilar, and P. M. Alzari, “The crystal structure of Trypanosoma cruzi arginine kinase,” Proteins, vol. 69, no. 1, pp. 209–212, 2007.

[60] C. Paveto, M. C. Giùdia, M. I. Esteva et al., “Anti-Trypanosoma cruzi activity of green tea (Camellia sinensis) catechins,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 1, pp. 69–74, 2004.

[61] X. Q. Wu, W. J. Zhu, Z. R. Lü et al., “The effect of rutin on arginine kinase: Inhibition kinetics and thermodynamics merging with docking simulation,” International Journal of Biological Macromolecules, vol. 44, no. 2, pp. 149–155, 2009.

[62] C. A. Pereira, G. D. Alonso, S. Ivaldi, L. A. Bouvier, H. N. Torres, and M. M. Flavià, “Screening of substrate analogs as potential enzyme inhibitors for the arginine kinase of Trypanosoma cruzi,” Journal of Eukaryotic Microbiology, vol. 50, no. 2, pp. 132–134, 2003.

[63] R. E. Parks Jr. and R. P. Aganwal, “9 Nucleoside Diphosphokinases,” Enzymes, vol. 8, pp. 307–333, 1973.

[64] I. Lascu and P. Gonin, “The catalytic mechanism of nucleoside diphosphate kinases,” Journal of Bioenergetics and Biomembranes, vol. 32, no. 3, pp. 237–246, 2000.

[65] M. L. Lacombe, L. Milon, A. Munier, J. G. Mehus, and D. O. Lambeth, “The human Nm23/Nucleoside diphosphate kinases,” Journal of Bioenergetics and Biomembranes, vol. 32, no. 3, pp. 247–258, 2000.

[66] J. Janin, C. Dumas, S. Moréra et al., “Three-dimensional structure of nucleoside diphosphate kinase,” Journal of Bioenergetics and Biomembranes, vol. 32, no. 3, pp. 215–225, 2000.

[67] S. M. King, “Axonemal protofilament ribbons, DM10 domains, and the link to juvenile myoclonic epilepsy,” Cell Motility and the Cytoskeleton, vol. 63, no. 5, pp. 245–253, 2006.

[68] C. M. Sadek, A. Jiménez, A. E. Damdimoopoulos et al., “Characterization of human thioredoxin-like 2: a novel microtubule-binding thioredoxin expressed predominantly in the cilia of lung airway epithelium and spermatid manchette and axoneme,” Journal of Biological Chemistry, vol. 278, no. 15, pp. 13133–13142, 2003.

[69] A. A. Bomaina, A. C. Molijn, M. Pestel, M. Veron, and P. J. M. Van Haastert, “Activation of G-proteins by receptor-stimulated nucleoside diphosphate kinase in dictyostelium,” EMBO Journal, vol. 12, no. 6, pp. 2275–2279, 1993.

[70] P. A. Randazzo, J. K. Northup, and R. A. Kahn, “Regulatory GTP-binding proteins (ADP-ribosylation factor, G(t), and RAS) are not activated directly by nucleoside diphosphate kinase,” Journal of Biological Chemistry, vol. 267, no. 25, pp. 18182–18189, 1992.

[71] Q. Lu, H. Park, L. A. Egger, and M. Inouye, “Nucleoside-diphosphate kinase-mediated signal transduction via histidyl-aspartyl phosphorelay systems in Escherichia coli,” Journal of Biological Chemistry, vol. 271, no. 51, pp. 32886–32893, 1996.

[72] N. J. MacDonald, A. De La Rosa, M. A. Benedict, J. M. P. Freije, H. Krutsch, and P. S. Steeg, “A serine phosphorylation of Nm23, and not its nucleoside diphosphate kinase activity, correlates with suppression of tumor metastatic potential,” Journal of Biological Chemistry, vol. 268, no. 34, pp. 25780–25789, 1993.

[73] P. D. Wagner, P. S. Steeg, and N. D. Vu, “Two-component kinase-like activity of nm23 correlates with its motility-suppressing activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 17, pp. 9000–9005, 1997.

[74] P. D. Wagner and N. D. Vu, “Phosphorylation of geranyl and farnesyl pyrophosphates by Nm23 proteins/nucleoside diphosphate kinases,” Journal of Biological Chemistry, vol. 275, no. 45, pp. 35570–35576, 2000.

[75] J. Biggs, E. Hersperger, P. S. Steeg, L. A. Liotta, and A. Shearn, “A Drosophila gene that is homologous to a mammalian gene associated with tumor metastasis codes for a nucleoside diphosphate kinase,” Cell, vol. 63, no. 5, pp. 933–940, 1990.

[76] J. D. Kantor, B. McCormick, P. S. Steeg, and B. R. Zetter, “Inhibition of cell motility after nm23 transfection of human and murine tumor cells,” Cancer Research, vol. 53, no. 9, pp. 1971–1973, 1993.

[77] E. H. Postel, S. J. Berberich, S. J. Flint, and C. A. Ferrone, “Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis,” Science, vol. 261, no. 5120, pp. 478–480, 1993.

[78] A. M. Rosengard, H. C. Krutzsch, A. Shearn et al., “Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development,” Nature, vol. 342, pp. 624, pp. 177–180, 1989.

[79] D. Lombardi, M. L. Lacombe, and M. G. Paggi, “nm23: unravelling its biological function in cell differentiation,” Journal of Cellular Physiology, vol. 182, no. 2, pp. 144–149, 2000.

[80] E. H. Postel, “Cleavage of DNA by human NM23-H2/nucleoside diphosphate kinase involves formation of a covalent protein-DNA complex,” Journal of Biological Chemistry, vol. 274, no. 32, pp. 22821–22829, 1999.

[81] E. H. Postel, S. J. Berberich, J. W. Rooney, and D. M. Kaetzel, “Human NM23/nucleoside diphosphate kinase regulates gene expression through DNA binding to nucleosome-hypersensitive transcriptional elements,” Journal of Bioenergetics and Biomembranes, vol. 32, no. 3, pp. 277–284, 2000.

[82] J. H. Yoon, P. Singh, D. H. Lee et al., “Characterization of the 3'→5' exonuclease activity found in human nucleoside diphosphate kinase 1 (NDK1) and several of its homologues,” Biochemistry, vol. 44, no. 48, pp. 15774–15786, 2005.

[83] Y. Yoshida and K. Hasunuma, “Light-dependent subcellular localization of nucleoside diphosphate kinase-1 in Neospora caninum,” FEBS Microbiology Letters, vol. 261, no. 1, pp. 64–68, 2006.
[84] A. K. Saini, K. Maithal, P. Chand et al., “Nuclear localization and in situ DNA damage by Mycobacterium tuberculosis nucleoside-diphosphate kinase,” Journal of Biological Chemistry, vol. 279, no. 48, pp. 50142–50149, 2004.

[85] M. Ioana Anderca, T. Furuchi, R. Pinonatto, and S. Muto, “Identification of a mitochondrial nucleoside diphosphate kinase from the green alga Dunaliella tertiolecta,” Plant and Cell Physiology, vol. 43, no. 11, pp. 1276–1284, 2002.

[86] J. Hammargren, T. Salinas, L. Maréchal-Drouard, and C. Knorr, “The pea mitochondrial nucleoside diphosphate kinase cleaves DNA and RNA,” FEBS Letters, vol. 581, no. 18, pp. 3507–3511, 2007.

[87] S. Q. Zhang, Y. Hu, and A. Y. Jong, “Temporal and spatial distributions of yeast nucleoside diphosphate kinase activities and its association with the Cdc5p,” Cellular & Molecular Biology Research, vol. 41, no. 5, pp. 333–346, 1995.

[88] R. S. Patel-King, O. Gorbatyuk, S. Takebe, and S. M. King, “Flagellar radial spokes contain a Ca-stimulated nucleoside diphosphate kinase,” Molecular Biology of the Cell, vol. 15, no. 8, pp. 3891–3902, 2004.

[89] M. Breitman, E. Ghedin, C. Hertz-Fowler et al., “The genome of the African trypanosome Trypanosoma brucei,” Science, vol. 309, no. 5733, pp. 416–422, 2005.

[90] M. R. Miranda, G. E. Canepa, L. A. Bouvier, and C. A. Pereira, “Trypanosoma cruzi: multiple nucleoside diphosphate kinase isoforms in a single cell,” Experimental Parasitology, vol. 120, no. 1, pp. 103–107, 2008.

[91] R. M. Uloa, J. P. Muschietti, M. Veron, H. N. Torres, and M. T. Téllez-Iñón, “Purification and characterization of a soluble nucleoside diphosphate kinase in Trypanosoma cruzi,” Molecular and Biochemical Parasitology, vol. 70, no. 1–2, pp. 119–129, 1995.

[92] J. A. Gómez Barroso, H. Pereira, M. Miranda, C. Pereira, R. C. Garratt, and C. F. Aguilar, “Protein preparation, crystallization and preliminary X-ray analysis of Trypanosoma cruzi nucleoside diphosphate kinase 1,” Acta Crystallographica Section F, vol. 66, no. 7, pp. 862–865, 2010.

[93] M. R. Miranda, G. E. Canepa, L. A. Bouvier, and C. A. Pereira, “Trypanosoma cruzi nucleoside diphosphate kinase 1 (TcNDPK1) has a broad nucleoside activity,” Parasitology, vol. 135, no. 14, pp. 1661–1666, 2008.

[94] E. H. Postel, “Multiple biochemical activities of NMD2/NDP kinase in gene regulation,” Journal of Bioenergetics and Biomembranes, vol. 35, no. 1, pp. 31–40, 2003.

[95] A. Debrabant and H. Nakhasi, “Programmed cell death in trypanosomatids: is it an altruistic mechanism for survival of the fittest?” Kinetoplastid Biology and Disease, vol. 2, article no. 7, 2003.

[96] I. Hunger-Glaser, A. Hemphill, T. Shalaby, M. Hänni, and T. Seebeck, “Nucleoside diphosphate kinase of Trypanosoma brucei,” Gene, vol. 257, no. 2, pp. 251–257, 2000.

[97] A. Geiger, C. Hirtz, T. Bécue et al., “Exocytosis and protein secretion in Trypanosoma,” BMC Microbiology, vol. 10, article no. 20, 2010.

[98] A. H. C. de Oliveira, J. C. Ruiz, A. K. Cruz, L. J. Greene, J. C. Rosa, and R. J. Ward, “Subproteomic analysis of soluble proteins of the microsomal fraction from two Leishmania species,” Comparative Biochemistry and Physiology, Part D, vol. 1, no. 3, pp. 300–308, 2006.

[99] B. K. Kolli, J. Kostal, O. Zaborina, A. M. Chakrabarty, and K. P. Chang, “Leishmania-released nucleoside diphosphate kinase prevents ATP-mediated cytolysis of macrophages,” Molecular and Biochemical Parasitology, vol. 158, no. 2, pp. 163–175, 2008.

[100] I. R. E. Nett, D. M. A. Martin, D. Miranda-Saavedra et al., “The phosphoproteome of bloodstream trypanosome brucei, causative agent of African sleeping sickness,” Molecular and Cellular Proteomics, vol. 8, no. 7, pp. 1527–1538, 2009.

[101] R. Broadhead, H. R. Dawe, H. Farr et al., “Flagellar motility is required for the viability of the bloodstream trypanosome,” Nature, vol. 440, no. 7081, pp. 224–227, 2006.

[102] D. M. Baron, K. S. Ralston, Z. P. Kabututu, and K. L. Hill, “Functional genomics in Trypanosoma brucei identifies evolutionarily conserved components of motile flagella,” Journal of Cell Science, vol. 120, no. 3, pp. 478–491, 2007.

[103] T. Ikeda, “NDP Kinase 7 is a conserve microtubule-binding protein preferentially expressed in ciliated cells,” Cell Structure and Function, vol. 35, pp. 23–30, 2010.

[104] L. H. Noda, “Adenylate kinase,” in The Enzymes, P. D. Boyer, Ed., vol. 8, pp. 279–305, Academic Press, New York, NY, USA, 3rd edition, 1973.

[105] S. P. Bessman and C. L. Carpenter, “The creatine-creatinine phosphate energy shuttle,” Annual Review of Biochemistry, vol. 54, pp. 831–862, 1985.

[106] P. P. Dzeja, R. I. Zeleznikar, and N. D. Goldberg, “Adenylate kinase: kinetic behavior in intact cells indicates it is integral to multiple cellular processes,” Molecular and Cellular Biochemistry, vol. 184, no. 1-2, pp. 169–182, 1998.

[107] A. J. Carrasco, P. P. Dzeja, A. E. Akseliev et al., “Adenylate kinase phosphotransfer communicates cellular energetic signals to ATP-sensitive potassium channels,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 13, pp. 7623–7628, 2001.

[108] M. Roselle Abraham, V. A. Selivanov, D. M. Hodgson et al., “Coupling of cell energetics with membrane metabolic sensing: integrative signaling through creatine kinase phosphotransfer disrupted by M-C gene knock-out,” Journal of Biological Chemistry, vol. 277, no. 27, pp. 24427–24434, 2002.

[109] T. Rose, M. Brune, A. Wittinghofer et al., “Structural and catalytic properties of a deletion derivative (Δ133–157) of Escherichia coli adenylate kinase,” Journal of Biological Chemistry, vol. 266, no. 17, pp. 10781–10786, 1991.

[110] C. Vonrhein, H. Bönisch, G. Schäfer, and G. E. Schulz, “The structure of a trimeric archaeal adenylate kinase,” Journal of Molecular Biology, vol. 282, no. 1, pp. 167–179, 1998.

[111] C. W. Müller and G. E. Schulz, “Structure of the complex of adenylate kinase from Escherichia coli with the inhibitor P.P-di(adenosine-5’)-pentaphosphate,” Journal of Molecular Biology, vol. 202, no. 4, pp. 909–912, 1988.

[112] E. Schiltz, S. Burger, R. Grafmuller, W. R. Deppert, W. Haehnel, and E. Wagner, “Primary structure of maize chloroplast adenylate kinase,” European Journal of Biochemistry, vol. 222, no. 3, pp. 949–954, 1994.

[113] V. Magolden, U. Oechsner, and W. Bandlow, “The complete nucleotide sequence of the gene coding for yeast adenylate kinase,” Current Genetics, vol. 12, no. 6, pp. 405–411, 1987.

[114] C. Rozario and M. Muller, “Primary structure of a putative adenylate kinase gene of Giardia lamblia,” Molecular and Biochemical Parasitology, vol. 71, no. 2, pp. 279–283, 1995.

[115] T. Ohama, A. Muto, and S. Osawa, “Spectinomycin operon of Micrococcus luteus: evolutionary implications of organization and novel codon usage,” Journal of Molecular Evolution, vol. 29, no. 5, pp. 381–395, 1989.

[116] K. Fukami-Kobayashi, M. Nosaika, A. Nakazawa, and M. Go, “Ancient divergence of long and short isoforms of adenylate kinase: molecular evolution of the nucleoside monophosphate kinase family,” FEBS Letters, vol. 385, no. 3, pp. 214–220, 1996.
[117] K. Wild, R. Grafmüller, E. Wagner, and G. E. Schulz, “Structure, catalysis and supramolecular assembly of adenylate kinase from maize,” *European Journal of Biochemistry*, vol. 250, no. 2, pp. 326–331, 1997.

[118] I. D. Dinbergs and D. G. Lindmark, “*Tritrichomonas foetus* purification and characterization of hydrogenosomal ATP:AMP phosphotransferase (adenylate kinase),” *Experimental Parasitology*, vol. 69, no. 2, pp. 150–156, 1989.

[119] J. E. Cronan Jr. and G. N. Godson, “Mutants of *Escherichia coli* with temperature-sensitive lesions in membrane phospholipid synthesis: genetic analysis of glycerol-3-phosphate acyltransferase mutants,” *Molecular & General Genetics*, vol. 116, no. 3, pp. 199–210, 1972.

[120] M. Konrad, “Molecular analysis of the essential gene for adenylate kinase from the fission yeast *Schizosaccharomyces pombe*,” *Journal of Biological Chemistry*, vol. 268, no. 15, pp. 11326–11334, 1993.

[121] M. Noguchi, T. Sawada, and T. Akazawa, “ATP-regenerating system in the cilia of *Paramecium caudatum*,” *Journal of Experimental Biology*, vol. 204, no. 6, pp. 1063–1071, 2001.

[122] P. Dzeja and A. Terzic, “Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing,” *International Journal of Molecular Sciences*, vol. 10, no. 4, pp. 1729–1772, 2009.

[123] H. Villa, Y. Pérez-Pertejo, C. García-Estrada et al., “Molecular and functional characterization of adenylate kinase 2 gene from *Leishmania donovani*,” *European Journal of Biochemistry*, vol. 270, no. 21, pp. 4339–4347, 2003.

[124] J. K. Ulschmid, S. Rahlfs, R. H. Schirmer, and K. Becker, “Adenylate kinase and GTP:AMP phosphotransferase of the malarial parasite *Plasmodium falciparum*: central players in cellular energy metabolism,” *Molecular and Biochemical Parasitology*, vol. 136, no. 2, pp. 211–220, 2004.

[125] M. Sanchez-Moreno, D. Lasztity, I. Coppens, and F. R. Opperdoes, “Characterization of carbohydrate metabolism and demonstration of glycosomes in a Phytomonas sp. isolated from *Euphorbia characias*,” *Molecular and Biochemical Parasitology*, vol. 54, no. 2, pp. 185–199, 1992.